<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073823</url>
  </required_header>
  <id_info>
    <org_study_id>4070</org_study_id>
    <nct_id>NCT04073823</nct_id>
  </id_info>
  <brief_title>A Study Evaluating FT-SW in Unilateral Breast Cancer-Related Lymphedema Patients</brief_title>
  <official_title>A Feasibility Study Evaluating Flexitouch® Plus With a Therapy Cycle Software Modification in Patients With Unilateral Breast Cancer-Related Lymphedema (BCRL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tactile Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tactile Medical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to demonstrate equivalency in treatment effect, as determined&#xD;
      by objective measurements, between the modified therapy cycle software and the FDA-cleared&#xD;
      Flexitouch therapy cycle software.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to unforeseen slow enrollment and a shift in corporate resources due to the COVID-19&#xD;
    impact.&#xD;
  </why_stopped>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Actual">February 8, 2020</completion_date>
  <primary_completion_date type="Actual">February 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lymphatic Activation</measure>
    <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
    <description>Comparison of the change in the rate of lymphatic propulsion events from the pre-treatment values to the post-treatment values for both the affected and contralateral limbs using the investigational technique of near infrared-fluorescent (NIRF) imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Swelling - MoistureMeterD</measure>
    <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
    <description>Comparison of the percent change in local tissue water from the pre-treatment values to the post-treatment values on the affected limb using MoistureMeterD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Swelling - Perometry</measure>
    <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
    <description>Swelling in the affected and contralateral limb as assessed using local tissue water content</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Thickness (Ultrasound)</measure>
    <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
    <description>Skin changes on the affected and contralateral limb as assessed by skin thickness (Ultrasound).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>24-Hour Follow-Up</time_frame>
    <description>Adverse events reported between treatment and the 24-hour follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Treatment Functional Vessel Assessment Via Near Infrared-fluorescent (NIRF) Imaging</measure>
    <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
    <description>Comparison of the number of subjects with an increase in vessels for both the affected and contralateral limbs via near infrared-fluorescent (NIRF) imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Projected Area or Extent of Dermal Backflow Via Near Infrared-fluorescent (NIRF) Imaging</measure>
    <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
    <description>Comparison of the change in dermal backflow from the pre-treatment values to the post-treatment values as the sum of the volume of area for all locations for both the affected and contralateral limbs via near infrared-fluorescent (NIRF) imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Swelling in the Affected and Contralateral Limb as Assessed Using: Perometry (LymphaTech 3D Scanner)</measure>
    <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
    <description>Compare the percent of participants by arm demonstrating a decrease in limb volume for the affected and contralateral limbs via Perometry (LymphaTech 3D Scanner)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Changes on the Affected and Contralateral Limb as Assessed by: Skin Thickness (Ultrasound)</measure>
    <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
    <description>Comparison of the percent of participants by arm demonstrating a decrease in thickness for each site, separating skin and subcutaneous changes, on the affected limb via Ultrasound</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Cancer Related Lymphedema</condition>
  <arm_group>
    <arm_group_label>Flexitouch Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Flexitouch Plus with SW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flexitouch Plus</intervention_name>
    <description>Flexitouch Plus full arm and core treatment</description>
    <arm_group_label>Flexitouch Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flexitouch Plus FT with software modification</intervention_name>
    <description>Flexitouch Plus full arm and trunk/chest treatment</description>
    <arm_group_label>Flexitouch Plus with SW</arm_group_label>
    <other_name>FT-SW</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female 18 years of age or older&#xD;
&#xD;
          -  Diagnosis of unilateral breast cancer-related lymphedema&#xD;
&#xD;
          -  Stage I or early stage II lymphedema without severe fibrosis at the time of enrollment&#xD;
&#xD;
          -  ≥ 5% volume difference between affected and unaffected arm as verified via perometry&#xD;
&#xD;
          -  Willing and able to give informed consent&#xD;
&#xD;
          -  Willing and able to comply with the study protocol requirements and all study-related&#xD;
             visit requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In-home use of PCD within previous 3 months&#xD;
&#xD;
          -  Therapist or self-administered manual lymph drainage (MLD) within previous 1 week&#xD;
&#xD;
          -  Mastectomy or lymph node removal on side without lymphedema&#xD;
&#xD;
          -  Bilateral lymphedema&#xD;
&#xD;
          -  Heart failure (acute pulmonary edema, decompensated acute heart failure)&#xD;
&#xD;
          -  Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute&#xD;
             pulmonary embolism)&#xD;
&#xD;
          -  Active skin or limb infection/inflammatory disease (acute cellulitis, other&#xD;
             uncontrolled skin or untreated inflammatory skin disease) on the arms or trunk&#xD;
&#xD;
          -  Active cancer (cancer that is currently under treatment, but not yet in remission)&#xD;
&#xD;
          -  Poorly controlled kidney disease (glomerular filtration rate &lt; 30 mls per minute),&#xD;
             hypoproteinemia, pulmonary hypertension, hypothyroidism, cyclic edema, or Munchausen&#xD;
             Syndrome&#xD;
&#xD;
          -  BMI &gt;50&#xD;
&#xD;
          -  Any circumstance where increased lymphatic or venous return is undesirable&#xD;
&#xD;
          -  Currently pregnant or trying to become pregnant&#xD;
&#xD;
          -  Allergy to iodine&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <results_first_submitted>December 2, 2020</results_first_submitted>
  <results_first_submitted_qc>January 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2021</results_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Unilateral Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Breast Cancer Lymphedema</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT04073823/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Flexitouch Plus</title>
          <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
        </group>
        <group group_id="P2">
          <title>Flexitouch Plus With SW</title>
          <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flexitouch Plus</title>
          <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
        </group>
        <group group_id="B2">
          <title>Flexitouch Plus With SW</title>
          <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="53" upper_limit="53"/>
                    <measurement group_id="B2" value="81" lower_limit="81" upper_limit="81"/>
                    <measurement group_id="B3" value="67" lower_limit="53" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lymphatic Activation</title>
        <description>Comparison of the change in the rate of lymphatic propulsion events from the pre-treatment values to the post-treatment values for both the affected and contralateral limbs using the investigational technique of near infrared-fluorescent (NIRF) imaging.</description>
        <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Plus</title>
            <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
          </group>
          <group group_id="O2">
            <title>Flexitouch Plus With SW</title>
            <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphatic Activation</title>
          <description>Comparison of the change in the rate of lymphatic propulsion events from the pre-treatment values to the post-treatment values for both the affected and contralateral limbs using the investigational technique of near infrared-fluorescent (NIRF) imaging.</description>
          <units>Percent Rate Change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Affected Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="-50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contralateral Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0"/>
                    <measurement group_id="O2" value="241.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Swelling - MoistureMeterD</title>
        <description>Comparison of the percent change in local tissue water from the pre-treatment values to the post-treatment values on the affected limb using MoistureMeterD.</description>
        <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Plus</title>
            <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
          </group>
          <group group_id="O2">
            <title>Flexitouch Plus With SW</title>
            <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Swelling - MoistureMeterD</title>
          <description>Comparison of the percent change in local tissue water from the pre-treatment values to the post-treatment values on the affected limb using MoistureMeterD.</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" lower_limit="-7.4" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-6.4" lower_limit="-11.4" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Swelling - Perometry</title>
        <description>Swelling in the affected and contralateral limb as assessed using local tissue water content</description>
        <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Plus</title>
            <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
          </group>
          <group group_id="O2">
            <title>Flexitouch Plus With SW</title>
            <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Swelling - Perometry</title>
          <description>Swelling in the affected and contralateral limb as assessed using local tissue water content</description>
          <units>Percent Change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Affected Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="-1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contralateral Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skin Thickness (Ultrasound)</title>
        <description>Skin changes on the affected and contralateral limb as assessed by skin thickness (Ultrasound).</description>
        <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Plus</title>
            <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
          </group>
          <group group_id="O2">
            <title>Flexitouch Plus With SW</title>
            <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Thickness (Ultrasound)</title>
          <description>Skin changes on the affected and contralateral limb as assessed by skin thickness (Ultrasound).</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Affected Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.1" lower_limit="-46.5" upper_limit="310.3"/>
                    <measurement group_id="O2" value="5.6" lower_limit="-17.0" upper_limit="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contralateral Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="-56.4" upper_limit="106.9"/>
                    <measurement group_id="O2" value="184.2" lower_limit="-4.3" upper_limit="670.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events</title>
        <description>Adverse events reported between treatment and the 24-hour follow-up</description>
        <time_frame>24-Hour Follow-Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Plus</title>
            <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
          </group>
          <group group_id="O2">
            <title>Flexitouch Plus With SW</title>
            <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Adverse events reported between treatment and the 24-hour follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-Treatment Functional Vessel Assessment Via Near Infrared-fluorescent (NIRF) Imaging</title>
        <description>Comparison of the number of subjects with an increase in vessels for both the affected and contralateral limbs via near infrared-fluorescent (NIRF) imaging.</description>
        <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Plus</title>
            <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
          </group>
          <group group_id="O2">
            <title>Flexitouch Plus With SW</title>
            <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Treatment Functional Vessel Assessment Via Near Infrared-fluorescent (NIRF) Imaging</title>
          <description>Comparison of the number of subjects with an increase in vessels for both the affected and contralateral limbs via near infrared-fluorescent (NIRF) imaging.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Affected Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contralateral Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Projected Area or Extent of Dermal Backflow Via Near Infrared-fluorescent (NIRF) Imaging</title>
        <description>Comparison of the change in dermal backflow from the pre-treatment values to the post-treatment values as the sum of the volume of area for all locations for both the affected and contralateral limbs via near infrared-fluorescent (NIRF) imaging</description>
        <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Plus</title>
            <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
          </group>
          <group group_id="O2">
            <title>Flexitouch Plus With SW</title>
            <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Projected Area or Extent of Dermal Backflow Via Near Infrared-fluorescent (NIRF) Imaging</title>
          <description>Comparison of the change in dermal backflow from the pre-treatment values to the post-treatment values as the sum of the volume of area for all locations for both the affected and contralateral limbs via near infrared-fluorescent (NIRF) imaging</description>
          <units>Percent Change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Affected Limb (Lateral Lower)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4"/>
                    <measurement group_id="O2" value="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contralateral Limb (Lateral Lower)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affected Limb (Medial Lower)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="-19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contralateral Limb (Medial Lower)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affected Limb (Medial Upper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contralateral Limb (Medial Upper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Swelling in the Affected and Contralateral Limb as Assessed Using: Perometry (LymphaTech 3D Scanner)</title>
        <description>Compare the percent of participants by arm demonstrating a decrease in limb volume for the affected and contralateral limbs via Perometry (LymphaTech 3D Scanner)</description>
        <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Plus</title>
            <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
          </group>
          <group group_id="O2">
            <title>Flexitouch Plus With SW</title>
            <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Swelling in the Affected and Contralateral Limb as Assessed Using: Perometry (LymphaTech 3D Scanner)</title>
          <description>Compare the percent of participants by arm demonstrating a decrease in limb volume for the affected and contralateral limbs via Perometry (LymphaTech 3D Scanner)</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Affected Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contralateral Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skin Changes on the Affected and Contralateral Limb as Assessed by: Skin Thickness (Ultrasound)</title>
        <description>Comparison of the percent of participants by arm demonstrating a decrease in thickness for each site, separating skin and subcutaneous changes, on the affected limb via Ultrasound</description>
        <time_frame>Baseline and following a single treatment, an average of one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Plus</title>
            <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
          </group>
          <group group_id="O2">
            <title>Flexitouch Plus With SW</title>
            <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Changes on the Affected and Contralateral Limb as Assessed by: Skin Thickness (Ultrasound)</title>
          <description>Comparison of the percent of participants by arm demonstrating a decrease in thickness for each site, separating skin and subcutaneous changes, on the affected limb via Ultrasound</description>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Skin Thickness (Site A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin Thickness (Site B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin Thickness (Site C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous Thickness (Site A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous Thickness (Site B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous Thickness (Site C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event assessment will occur during the acute study period and ~24 hours after the acute study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Flexitouch Plus</title>
          <description>Flexitouch Plus: Flexitouch Plus full arm and core treatment</description>
        </group>
        <group group_id="E2">
          <title>Flexitouch Plus With SW</title>
          <description>Flexitouch Plus FT with software modification: Flexitouch Plus full arm and trunk/chest treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrea Stone</name_or_title>
      <organization>Tactile Medical</organization>
      <phone>612.540.5267</phone>
      <email>astone@tactilemedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

